Friday, July 10, 2026
🇺🇸 FDA

pharma · Multiple Myeloma · Relapsed/Refractory Multiple Myeloma

Janssen-Cilag International N.V

Janssen-Cilag International N.V.

Janssen-Cilag International N.V clinical programs — 67 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
São Paulo, EU HQ
13 Employees
EMA registrant Type
Company details
Status
Public
HQ
São Paulo, EU
Employees
13
Programs
161
Drugs
159
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Janssen-Cilag International N.V projects

67 ClinicalTrials.gov programs sponsored by Janssen-Cilag International N.V.

Janssen-Cilag International N.V has 67 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

67 programs

Clinical programs

Page 1 of 2

  1. 17000139BLC3001

    Janssen-Cilag International N.V.

    Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder

    phase 3 small molecule active

    1 trial

  2. 17000139BLC3002

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  3. 17000139BLC3004

    Janssen-Cilag International N.V.

    High-Risk Non-muscle-invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. 42756493BLC3001

    Janssen-Cilag International N.V.

    Advanced Urothelial Cancer

    phase 3 small molecule active

    1 trial

  5. 42756493BLC3004

    Janssen-Cilag International N.V.

    FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  6. 42756493BLC3005

    Janssen-Cilag International N.V.

    High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations

    phase 3 small molecule active

    1 trial

  7. 54135419SUI3003

    Janssen-Cilag International N.V.

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  8. 54767414AMY3001

    Janssen-Cilag International N.V.

    AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)

    phase 3 small molecule active

    1 trial

  9. 54767414MMY3019

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  10. 56021927PCR3001

    Janssen-Cilag International N.V.

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  11. 56021927PCR3002

    Janssen-Cilag International N.V.

    Metastatic Hormone-sensitive Prostate Cancer

    phase 3 small molecule active

    1 trial

  12. 56021927PCR3015

    Janssen-Cilag International N.V.

    High risk recurrent prostate cancer previously treated with radical prostatectomy

    phase 3 small molecule active

    1 trial

  13. 61186372COR3001

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    phase 3 small molecule active

    1 trial

  14. 61186372COR3002

    Janssen-Cilag International N.V.

    KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  15. 61186372HNC3001

    Janssen-Cilag International N.V.

    Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  16. 61186372NSC3001

    Janssen-Cilag International N.V.

    EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  17. 61186372NSC3002

    Janssen-Cilag International N.V.

    Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  18. 61186372NSC3004

    Janssen-Cilag International N.V.

    EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  19. 64007957MMY3005

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  20. 64007957MMY3006

    Janssen-Cilag International N.V.

    Relapsed/refractory multiple myeloma

    phase 3 small molecule active

    1 trial

  21. 64091742PCR3001

    Janssen-Cilag International N.V.

    Metastatic Prostate Cancer

    phase 3 small molecule active

    1 trial

  22. 64407564MMY3002

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  23. 64407564MMY3009

    Janssen-Cilag International N.V.

    Relapsed or Refractory Myeloma

    phase 3 small molecule active

    1 trial

  24. 67652000PCR3002

    Janssen-Cilag International N.V.

    Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

    phase 3 small molecule active

    1 trial

  25. 68284528MMY3002

    Janssen-Cilag International N.V.

    Relapsed and Lenalidomide-Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  26. 68284528MMY3004

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  27. 73841937NSC3003

    Janssen-Cilag International N.V.

    EGFR-mutated locally advanced or metastatic Non Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  28. 75276617AML3001

    Janssen-Cilag International N.V.

    Acute Myeloid Luekemia

    phase 3 small molecule active

    1 trial

  29. 77242113CRD3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  30. 77242113PSA3001

    Janssen-Cilag International N.V.

    Active Psoriatic Arthritis

    phase 3 small molecule active

    1 trial

  31. 77242113PSO3001

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  32. 77242113PSO3002

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  33. 77242113PSO3003

    Janssen-Cilag International N.V.

    Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  34. 77242113PSO3004

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  35. 77242113PSO3006

    Janssen-Cilag International N.V.

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  36. 78278343PCR3001

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  37. 78278343PCR3003

    Janssen-Cilag International N.V.

    Metastatic Castration-resistant Prostate Cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  38. 79635322MMY3001

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  39. 80202135EBF3001

    Janssen-Cilag International N.V.

    Hemolytic Disease of the Fetus and Newborn (HDFN)

    phase 3 small molecule active

    1 trial

  40. 80202135FNAIT3001

    Janssen-Cilag International N.V.

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    phase 3 small molecule active

    1 trial

  41. 80202135FNAIT3003

    Janssen-Cilag International N.V.

    Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)

    phase 3 small molecule active

    1 trial

  42. 80202135SJS3001

    Janssen-Cilag International N.V.

    Sjögren's Disease

    phase 3 small molecule active

    1 trial

  43. 80202135SLE3001

    Janssen-Cilag International N.V.

    Systemic Lupus Erythematosus

    phase 3 small molecule active

    1 trial

  44. CNTO1275JPA3001

    Janssen-Cilag International N.V.

    Juvenile psoriatic arthritis

    phase 3 small molecule active

    1 trial

  45. CNTO1959CRD3001

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  46. CNTO1959CRD3004

    Janssen-Cilag International N.V.

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  47. CNTO1959CRD3005

    Janssen-Cilag International N.V.

    Fistulizing perianal Crohn's Disease

    phase 3 small molecule active

    1 trial

  48. CNTO1959CRD3008

    Janssen-Cilag International N.V.

    Crohn’s Disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Janssen-Cilag International N.V have?

67 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.